Skip to main content
NCBI home page
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2021 Sep 20;12:741716. doi: 10.3389/fphar.2021.741716

The Clinical Efficacy and Safety of 11 Commonly Used Treatment Strategies Improving Arrhythmia of CHD in China: A Network Meta-Analysis

Tao Wang 1, Wei Li 1, Qianqian Huang 1, Chuqiao Yuan 1, Liping Qu 1, Xiaohe Xiao 2, Wenjun Zou 1,*
PMCID: PMC8488134  PMID: 34616301

Abstract

Purpose: Arrhythmia which as a common complication of CHD, has a high incidence. At present, more and more anti-arrhythmic drugs are used in clinical practice. However, which drug has the best efficacy and high safety is still unknown. Therefore, we decided to use NMA to solve this problem.

Method: We searched CNKI, Wanfang database, VIP database, Pubmed, Embase and Cochrane libraries, and collected all RCTs of arrhythmia of CHD, and used RevMan (5.3) and Stata (13.0) to carry out this NMA. The primary outcome indicator of this study is efficiency; the secondary outcome indicator is the incidence of adverse reactions.

Result: A total of 134 RCTs, 13,951 patients, and 11 treatment strategies were included in this NMA. The results show that all treatment strategies can effectively improve the arrhythmia of patients. Among them, PMA+AM, AM+AT, AM+WG have higher effective rates, and PMA+AM, WG+ME, SC+ME have better safety. The effectiveness and safety of the treatment strategies which combined TCM and chemical drugs, are significantly better than that of using chemical drugs alone.

Conclusion: The treatment strategy of combination of multiple drugs usually has higher efficiency and safety. PMA+AM seems to be the most recommended treatment strategy. In addition, the rational combination of TCM and chemical drugs may provide potential benefit.

Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42021229693.

Keywords: arrhythmia, clinical efficacy, safety, network meta-analysis, systematic review

Introduction

Arrhythmias of coronary heart disease (CHD) are caused by the imbalance of myocardial electrical activity due to the stenosis or occlusion of the coronary lumen, and its incidence is as high as 40–75% (Kai-Qiang et al., 2019). In addition, the incidence of arrhythmia in elderly patients is higher, such as, the incidence of arrhythmia in people over 75 years old can be as high as 69% (Katta et al., 2020). Arrhythmia of CHD is mainly divided into sinus tachycardia, bradycardia, atrial or ventricular premature beats, supraventricular or ventricular tachycardia, ventricular fibrillation, and atrial fibrillation (Gladding et al., 2019). At present, the commonly used treatments for arrhythmia of CHD include: radiofrequency catheter ablation (RFCA), pacemaker implantation, and drug therapy (sodium channel blockers, β-adrenergic receptor blockers, calcium antagonists, etc.) (Zhang et al., 2019; Ye et al., 2021).

It has been reported that RFCA has a low success rate in areas such as ventricular, atrial, junctional premature beats and tachycardia (Zagkli et al., 2021), and pacemakers are expensive, and patients are afraid of implanting pacemakers (Klotzbaugh et al., 2020). However, drug therapy has become the most commonly used therapeutic strategy due to its efficacy and low treatment cost (Gaur et al., 2020). However, although antiarrhythmic drugs can reduce arrhythmia in patients through various ways, their effective rate is unstable and has different degrees of side effects, such as gastrointestinal toxicity, liver injury, cardiotoxicity, and allergic reactions. In addition, patients with structural heart disease have a higher risk of developing ventricular arrhythmias after using antiarrhythmic drugs (Shi, 2020). Therefore, it is particularly important to comprehensively evaluate the clinical efficacy and safety of commonly used clinical antiarrhythmic drugs to determine the most potential therapeutic strategy.

There are eight kinds of antiarrhythmic drugs which the most commonly used in China. Among them, Wenxin Granules (WG) and Shensong Yangxin Capsules (SC) are traditional Chinese medicines, while amiodarone (AM), metoprolol (ME), atenolol (AT), potassium magnesium aspartate (PMA), propafenone (PR) and lidocaine (LI) are chemical drugs. In this study, the network meta-analysis method was adopted to evaluate the clinical efficacy and safety of 11 treatment strategies including the above eight drugs, in order to provide reference for the clinical treatment of arrhythmia of CHD.

Materials and Methods

Search Strategy

This research protocol has been registered and approved on the international prospective register of systematic reviews (PROSPERO) on February 6, 2020. The registration number is: CRD42021229693. This study will be implemented in strict accordance with the registered research protocol. We searched China National Knowledge Infrastructure (CNKI), Wanfang Database, VIP medicine information system, PubMed, Embase and Cochrane Libraries over a period of time from the establishment of the database to February 2021. The initial search items were used as follows: “arrhythmia”, “coronary heart disease” (title/abstract) and “randomized controlled trial”(title/abstract). The inclusion criteria were as follows: 1) RCTs related to arrhythmia of CHD. 2) All patients were diagnosed as arrhythmia of CHD in accordance with clear diagnostic criteria. 3) The gender and age of patients were not limited. 4) The language of the literature is not limited. The exclusion criteria were as follows: 1) Repetitive published studies. 2) Studies with incomplete or incorrect data. 3) Animal experiments and literature review. In this study, three researchers (Tao Wang, Wei Li, and Qianqian Huang) independently extracted data. In addition, a review team of two researchers (Wenjun Zou, Liping Qu) checked the accuracy of the data and assessed the quality of the included studies. Basic information of the included studies was recorded (name of the study included, number of patients, therapeutic strategies, mode of administration, dose administered, course of treatment, outcome, etc.) and relevant data were extracted. The Cochrane Risk of Bias tool was used to assess the quality of the included studies. All the differences that occurred in the study were discussed by review team.

Statistical Analysis

We performed this study using RevMan (5.3) and Stata (13.0) and constructed a treatment strategy network. For the dichotomous variable, we calculated the odds ratios (ORs), and all of them were expressed with 95% CI. In order to make the results of this study more accurate, we adopted the random effect model and the inconsistency model to carry out this study. We first compared all the treatment strategies pairwise and calculated their ORs. For all primary and secondary outcomes, additional contour line funnel plot were used to detect publication bias, and trim and fill method were used to evaluate the stability of the results. Finally, we used the surface under the cumulative ranking curve (SUCRA) to rank the efficacy of the treatment strategy in each outcome. In addition, we did this NMA within a frequentist framework. Funders did not intervene in study design, data collection, data analysis, data interpretation and article writing.

Results

Quality and Characteristics of the Included Studies

A total of 3,093 studies were retrieved through the search strategy. Two thousand one hundred and sixty-two duplicate reports, 83 reviews, 609 animal studies, and 105 clinical studies that did not conform to the randomized control principle were excluded. In the end, 134 studies were included (Figure 1A) (Bai, 2019; Chen and Lin, 2015; Chen and Hu, 2020; Chen, 2019a; Chen et al., 2012; Chen and Wei, 2019; Chen, 2019b; Chen, 2017; Cheng et al., 2019; Dong, 2018a; Dong, 2018b; Duan, 2016; Er, 2020; Fan, 2020; Fan, 2019; Fang, 2018; Feng, 2017a; Feng, 2017b; Feng et al., 2017; Gao, 2018; Gao, 2015; Gao, 2020; Gong and Wan, 2019; Guo, 2018a; Guo, 2018b; Guo and Tai, 2020; Han and Wang, 2014; He et al., 2020; Hou, 2018; Hou, 2019; Hou et al., 2015; Hu and Yang, 2018; Yang, 2018; Yang and Xi, 2020; Ye, 2012; Yi, 2018; Yi, 2019; You, 2017; Yu, 2018; Yu, 2020; Yu et al., 2015; Yuan, 2017; Yue, 2018; Zeng, 2016; Zhang, 2020b; Zhang, 2017b; Zhang, 2018a; Zhang, 2018b; Zhang et al., 2016b; Zhang and Zhang, 2013; Zhang, 2016a; Zhang, 2016b; Zhang, 2019c; Zhang, 2017a; Zhang, 2019a; Zhang, 2019d; Zhang, 2019b; Zhang, 2015; Zhang, 2020a; Zhang et al., 2016a; Zhao and Long, 2017; Zhao et al., 2020; Zhao, 2018; Zhen, 2019; Zhou, 2016a; Zhou, 2016b; Zhou, 2019; Zhou, 2015a; Zhou, 2015b; Zhu, 2019; Zhu, 2018; Zhuang, 2017; Hu, 2016; Huang, 2016; Huang, 2018; Huo, 2019a; Huo, 2019b; Jiang et al., 2017; Jin et al., 2018; Jin, 2019; Ju, 2016; Li, 2020c; Li, 2018a; Li, 2020b; Li et al., 2018; Li, 2020a; Li et al., 2020b; Li, 2020d; Li et al., 2020a; Li, 2018b; Li, 2014; Liang, 2018; Lie, 2018; Liu, 2017; Liu, 2018a; Liu and Wang, 2015; Liu, 2018b; Long, 2019; Luo, 2016; Lv et al., 2020; Meng, 2018; Pan et al., 2017; Peng, 2017; Peng and Liu, 2019; Qian, 2015; Qu, 2016; Ren, 2018; Ren, 2020; Ruan, 2020; Song et al., 2019; Sun and Gu, 2019; Sun, 2018; Sun, 2020; Tan et al., 2020; Wang et al., 2018b; Wang, 2018b; Wang et al., 2018a; Wang, 2013; Wang, 2018a; Wang, 2016; Wang et al., 2020; Wang, 2020; Wang and Qi, 2016; Wang, 2017; Wu, 2016; Xiao et al., 2017; Xu, 2019a; Xu, 2019b; Xu, 2018; Xun, 2017; Xun, 2020; Yang and Zhang, 2019; Yang et al., 2017; Yang, 2017). This study involved a total of 11 treatment strategies (Figure 1B). Among the included studies, 130 studies clearly reported the randomization method adopted, and four studies did not clearly report the randomization method. The data of 134 studies are complete. In addition, three studies clearly reported the type of blinding used. There are no selective reports in all the included studies. We assessed the quality of included studies in accordance with the Cochrane risk-of-bias tool. Each evaluation principle was divided into “high risk,” “low risk,” and “unclear” (Figure 1C). It can be seen that there is no high risk in the included studies. All the studies included in this study were designed in parallel, and the test sites were all in China. All patients were diagnosed as arrhythmia of CHD in regular hospitals according to clear diagnostic criteria. This study involved 13,951 patients. The number of men and women is roughly equal, and the average age is about 57 years old. The basic information of the studies included in this article is listed in Supplementary Table S1.

FIGURE 1.

FIGURE 1

Open in a new tab

(A) Flowchart of studies selection; (B) Network of comparisons included in the analysis; (C) Methodological quality assessment of the risk of bias for included studies.

Primary Outcome

The primary outcome indicator of our study is effective rate. And all the included studies reported on this indicator. In order to correct the possible heterogeneity within the study, we decided to use the random effects model to calculate the ORs. We use Stata (13.0) to perform a mixed comparison of all treatment strategies, and obtain the superiority of each treatment strategy compared to other treatment strategies (Supplementary Table S2). Then we draw SUCAR to further comprehensively rank the improvement of the main outcome of these 11 treatment strategies to further explore which treatment strategy is the best (Figure 2A). The results found that PMA+AM, AM+AT, AM+WG are the top three treatment strategies, followed by ME+AM, WG+ME, SC+ME, AM, ME, PR, LI, and CT. Since the combined OR value of each treatment strategy is derived from direct comparison and indirect comparison between treatment strategies, in order to further verify the accuracy of the results of this study, we used trim and fill method to perform a sensitivity analysis on this outcome (Figure 2B). It was found that filling the blank sample did not cause a significant change in the OR value, so the results of this study are stable.

FIGURE 2.

FIGURE 2

Open in a new tab

(A) Ranking for efficacy of 11 treatment strategies; (B) Sensitivity analysis of this study.

Secondary Outcome

The primary outcome indicator of our study is adverse reaction rate. 88 studies have reported on this indicator, and the main adverse reactions include digestive tract reactions, allergic reactions, hypotension, central nervous system reactions, arrhythmia, abnormal liver function, etc. We use Stata (13.0) to perform a mixed comparison of all treatment strategies, and obtain the superiority of each treatment strategy compared to other treatment strategies (Supplementary Table S3). Then we draw SUCAR to further comprehensively rank the improvement of the secondary outcome of these 11 treatment strategies to further explore which treatment strategy is the best (Figure 3A). We ranked all treatment strategies according to the SUCRA value. The larger the SUCRA value, the lower the incidence of adverse reactions. The results found that PMA+AM, WG+ME, SC+ME are the top three treatment strategies, followed by AM+WG, ME, AM+AT, AM+ME, AM, CT, PR, and LI. Since the combined OR value of each treatment strategy is derived from direct comparison and indirect comparison between treatment strategies, in order to further verify the accuracy of the results of this study, we used trim and fill method to perform a sensitivity analysis on this outcome (Figure 3B). It was found that filling the blank sample did not cause a significant change in the OR value, so the results of this study are stable.

FIGURE 3.

FIGURE 3

Open in a new tab

(A) Ranking for adverse reaction rate of 11 treatment strategies; (B) Sensitivity analysis of this study.

Bias Analysis

In order to observe whether the results of this study are affected by reporting bias, we draw a additional contour line funnel plot. The results show that most of the studies are located in the upper part of the additional contour line funnel plot, indicating that the dispersion of the samples is low. In addition, the results of the bias test showed that most samples did not have significant reporting bias (p > 0.05). Therefore, the results of this study are accurate and stable.

Discussion

In recent years, studies have shown that more and more patients with coronary heart disease combined with arrhythmia, more than 90% of sudden cardiac deaths are induced by arrhythmia (Yan-Hua, 2018; Dong et al., 2019). However, while the currently commonly used antiarrhythmic drugs improve arrhythmia in patients, there are also many adverse reactions such as promoting arrhythmia. This study conducted a comprehensive evaluation of 11 antiarrhythmic drug therapies frequently used in clinical. All treatment strategies can significantly improve the patient’s arrhythmia, PMA+AM, AM+AT, AM+WG are the top three treatment strategies. In terms of safety, PMA+AM, WG+ME, and SC+ME are the top three treatment strategies. In addition, this study also observed the bias and stability of each outcome, and found no significant bias and instability, which also enhanced the accuracy of the results of this study. However, it should be noted that in the two outcomes of this study, the SUCRA values of the top three treatment strategies are very close. Therefore, although they have significant advantages over other treatment strategies, they do not represent the advantages and disadvantages of the three of them. However, PMA+AM ranks first in the SUCRA value of the two outcome indicators, which seems to indicate that it is the most recommended treatment strategy.

AM as a broad-spectrum antiarrhythmic drug, has the most clinical application at present. It has a good effect on a variety of arrhythmias, but the incidence of adverse reactions is about 80%, and the main adverse reactions include thyroid toxicity, gastrointestinal toxicity, abnormal liver function, etc. (Lavon and Goldman, 2019) PMA can increase myocardial energy supply and reduce myocardial energy consumption. It has a good anti-arrhythmic effect, but there are also adverse reactions such as nausea, vomiting, chest tightness, and vascular irritation pain (Yong, 2013). The combination of the two can significantly improve the incidence of arrhythmias, and also significantly reduce the incidence of adverse reactions such as vomiting, liver function decline and thyroid function decline. This may be because the combination reduces the dose of the drug used alone.

In addition, it is worth mentioning that among the 11 treatment strategies involved in this study, three of them were combined application of chemical drugs and TCM (WG+ME, SC+ME, AM+WG). WG and SC which commonly used anti-arrhythmia drugs in China are included in Chinese pharmacopoeia, and they have definite efficacy and good safety (Shi-Jun, 2019; Shi et al., 2020). This study showed that the anti-arrhythmic efficacy of WG+ME, SC+ME and AM+WG was significantly better than that of AM and ME alone, indicating that TCM could significantly improve the anti-arrhythmic efficiency of chemical drugs, and AM+WG ranked in the top three. From the perspective of drug safety, the safety of WG+ME, SC+ME and AM+WG was also significantly better than that of AM and ME alone. This indicates that the combination of TCM with chemical drugs can significantly reduce the incidence of adverse reactions when chemical drugs are used alone, and WG+ME and SC+ME are the top three in the safety ranking. As a characteristic treatment strategy in China, traditional Chinese medicine can not only significantly improve the efficacy of chemical drugs against arrhythmia, but also have more potential in reducing the incidence of adverse reactions of chemical drugs.

Although there are slight instability and bias in the results of this study and there are limitations in the quality of RCTs, these have reduced the strength of the NMA. However, overall, this NMA still provides clinicians with detailed comparisons of common therapeutic strategies and provides reference for clinical use. The effectiveness and safety of these drugs in the treatment of arrhythmia of CHD need to be further validated in future clinical studies. Several large-scale and high quality randomized uniform criteria are needed to further confirm its effectiveness and safety.

Conclusion

This article shows that all the 11 treatment strategies concerned in this study can effectively improve arrhythmia of CHD. Among them, PMA+AM, AM+AT, AM+WG have a higher total effective rate, and PMA+AM, WG+ME, SC+ME have a lower incidence of adverse reactions. PMA+AM seems to be the most recommended intervention. In addition, the combination of multiple drugs usually has better efficiency and lower incidence of adverse reactions, especially the combination of TCM and chemical drugs has more potential in improving the effectiveness and safety of anti-arrhythmia. In short, this NMA provides clinicians with a detailed evaluation of the advantages of a variety of common anti-arrhythmic treatment strategies, and provides clinicians with medication references.

Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

Author Contributions

In this study, TW, WL, and QH independently extracted data. WZ, LQ checked the accuracy of the data and assessed the quality of the included studies. CY, XX wrote this article.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2021.741716/full#supplementary-material

Click here for additional data file. (13.5KB, docx)
Click here for additional data file. (155.7KB, docx)
Click here for additional data file. (20.4KB, xlsx)

References

  1. Bai S. (2019). Observation on the Clinical Effect of Amiodarone Combined With Metoprolol in the Treatment of Coronary Heart Disease and Arrhythmia. Guide China Med. (14), 98. 10.16282/j.cnki.cn11-9336/r.2019.26.026 [DOI] [Google Scholar]
  2. Chen D. J., Lin Y. T. (2015). The Effect of Amiodarone in the Treatment of Coronary Heart Disease, Chronic Heart Failure and Ventricular Arrhythmia. China Med. Pharm. (20), 28–30+36. 10.19347/j.cnki.2096-1413.201831059 [DOI] [Google Scholar]
  3. Chen F., Hu Y. Z. (2020). Therapeutic Analysis of Shensongyangxin Capsule Combined With Highly Selective Β-1 Receptor Blocker in the Treatment of Coronary Heart Disease With Ventricular Arrhythmia. Public Med. Forum Mag. (23), 3349–3350. 10.16282/j.cnki.cn11-9336/r.2019.11.010 [DOI] [Google Scholar]
  4. Chen G. (2019). Clinical Effect Observation of Atenolol Combined With Amiodarone in the Treatment of Coronary Heart Disease With Arrhythmia. Cardiovasc. Dis. J. Integr. Trad. Chin. West. Med. (15), 30–31. 10.16662/j.cnki.1674-0742.2017.10.151 [DOI] [Google Scholar]
  5. Chen H., Wang X., Chen Z. X. (2012). Observation on the Therapeutic Effect of Metoprolol Combined With Wenxin Granule on Ventricular Arrhythmia Of Coronary Heart Disease. Seek Med. (10), 500. 10.14163/j.cnki.11-5547/r.2015.20.108 [DOI] [Google Scholar]
  6. Chen J., Jie Y., Wei W. Q. (2019). The Efficacy of Amiodarone Combined With Metoprolol in the Treatment of Coronary Heart Disease With Arrhythmia. Shenzhen J. Integr. Tradit. Chin. West. Med. (12), 104–105. 10.19435/j.1672-1721.2019.31.017 [DOI] [Google Scholar]
  7. Chen T. (2019). Clinical Efficacy And Safety of Wenxin Granule Combined With Amiodarone in the Treatment of Coronary Heart Disease With Arrhythmia. J. Clin. Rational Drug Use (12), 1–2+5. 10.15887/j.cnki.13-1389/r.2020.12.020 [DOI] [Google Scholar]
  8. Chen X. L. (2017). Therapeutic Effect of Wenxin Granule Combined With Amiodarone in the Treatment of Coronary Heart Disease Arrhythmia. China Foreign Med. Treat. 10, 151–153. 10.16281/j.cnki.jocml.2018.19.097 [DOI] [Google Scholar]
  9. Cheng Q. L., Liu F. R., Gao S. (2019). To Explore the Clinical Efficacy and Safety Analysis of Wenxin Granule Combined With Amiodarone in the Treatment of Patients With Coronary Heart Disease and Arrhythmia. Sichuan J. Anat. (2), 52–53. 10.15887/j.cnki.13-1389/r.2019.12.001 [DOI] [Google Scholar]
  10. Dong C. F. (2018). Shensongyangxin Capsule Combined With Metoprolol Succinate in the Treatment of 53 Cases of Coronary Heart Disease With Ventricular Arrhythmia. Jiangxi J. Traditional Chin. Med. 10, 41–43. 10.19347/j.cnki.2096-1413.202027015 [DOI] [Google Scholar]
  11. Dong Q. J. (2018). Clinical Study of Amiodarone in the Treatment of Coronary Heart Disease With Chronic Heart Failure and Ventricular Arrhythmia. Chin. J. Rational Drug Use (8), 40–43. 10.19787/j.issn.1008-1879.2020.03.018 [DOI] [Google Scholar]
  12. Dong Y., Chen H., Gao J., Liu Y., Li J., Wang J. (2019). Molecular Machinery and Interplay of Apoptosis and Autophagy in Coronary Heart Disease. J. Mol. Cell Cardiol. 136, 27–41. 10.14163/j.cnki.11-5547/r.2010.26.02110.1016/j.yjmcc.2019.09.001 [DOI] [PubMed] [Google Scholar]
  13. Duan Q. (2016). The Effectiveness of Amiodarone in Emergency Coronary Heart Disease Tachyarrhythmia. Chin. Med. Innov. 7, 126–128. 10.16282/j.cnki.cn11-9336/r.2016.03.021 [DOI] [Google Scholar]
  14. Er C. Z. (2020). Comparison of the Curative Effect of Amiodarone Hydrochloride and Lidocaine in the Treatment of Coronary Heart Disease Complicated With Arrhythmia. Jilin Med. J. (4), 888–889. 10.19613/j.cnki.1671-3141.2018.40.101 [DOI] [Google Scholar]
  15. Fan D. (2020). Clinical Observation of Amiodarone Combined with Metoprolol in the Treatment of Elderly Coronary Heart Disease with Arrhythmia. Cardiovasc. Dis. J. Integr. Tradit. Chin. West. Med. (13), 67+71. 10.16282/j.cnki.cn11-9336/r.2019.15.019 [DOI] [Google Scholar]
  16. Fan Y. (2019). Clinical Observation of Amiodarone in the Treatment of Ventricular Arrhythmia in Elderly Patients With Coronary Heart Disease. Knowledge Cardiovasc. Dis. Prev. Treat. (36), 28–29. 10.19613/j.cnki.1671-3141.2018.40.121 [DOI] [Google Scholar]
  17. Fang X. G. (2018). Application of Amiodarone in Tachyarrhythmia of Coronary Heart Disease and its Influence on Changes of ECG. Knowledge Cardiovasc. Dis. Prev. Treat. (4), 52–54. 10.14163/j.cnki.11-5547/r.2019.13.046 [DOI] [Google Scholar]
  18. Feng Q. (2017). Observation on the Effect of Wenxin Granule Combined With Metoprolol in the Treatment of Coronary Heart Disease Arrhythmia and its Improvement on Cardiac Function. J. China Prescription Drug (10), 95–96. 10.14163/j.cnki.11-5547/r.2019.13.046 [DOI] [Google Scholar]
  19. Feng Y. Q. (2017). The Clinical Value of Amiodarone in Emergency Treatment Of Coronary Heart Disease With Tachyarrhythmia. J. Clin. Med. Lit. (3), 426. 10.19347/j.cnki.2096-1413.201706011 [DOI] [Google Scholar]
  20. Feng Z. K., Wang H. L., Yang N. (2017). Effect of Wenxin Granules Combined with Amiodarone on Ventricular Arrhythmia of Coronary Heart Disease. Shaanxi J. Traditional Chin. Med. (7), 857–858. 10.16281/j.cnki.jocml.2019.45.148 [DOI] [Google Scholar]
  21. Gao J. L. (2018). Clinical Observation of Wenxin Granule Combined With Amiodarone in the Treatment of 208 Cases of Coronary Heart Disease With Ventricular Arrhythmia. Strait Pharm. J. (8), 127–129. 10.19613/j.cnki.1671-3141.2017.67.072 [DOI] [Google Scholar]
  22. Gao Q. N. (2015). Clinical Effect of Wenxin Granule Combined With Metoprolol Tartrate in the Treatment of Elderly Patients With Coronary Heart Disease and Arrhythmia. China J. Pharm. Econ. (10), 54–55. 10.19621/j.cnki.11-3555/r.2015.10.049 [DOI] [Google Scholar]
  23. Gao S. W. (2020). The Effect of Metoprolol Combined With Amiodarone in the Treatment Of Coronary Heart Disease With Arrhythmia. Henan Med. Res. (17), 3175–3177. 10.14164/j.cnki.cn11-5581/r.2020.03.063 [DOI] [Google Scholar]
  24. Gaur N., Ortega F., Verkerk A. O., Mengarelli I., Krogh-Madsen T., Christini D. J., et al. (2020). Validation of Quantitative Measure of Repolarization Reserve as a Novel Marker of Drug Induced Proarrhythmia. J. Mol. Cell Cardiol 145, 122–132. 10.1016/j.yjmcc.2020.04.019 [DOI] [PubMed] [Google Scholar]
  25. Gladding P. A., Legget M., Fatkin D., Larsen P., Doughty R. (2019). Polygenic Risk Scores in Coronary Artery Disease and Atrial Fibrillation. Heart Lung Circ. 29 (4), 634–640. 10.1097/HCO.000000000000062910.1016/j.hlc.2019.12.004 [DOI] [PubMed] [Google Scholar]
  26. Gong G. P., Wan C. (2019). Clinical Effect Observation of Wenxin Granule Combined With Metoprolol in the Treatment of Coronary Heart Disease Arrhythmia. Chin. Med. Innov. (12), 63–66. 10.16282/j.cnki.cn11-9336/r.2017.21.026 [DOI] [Google Scholar]
  27. Guo L. (2018). Efficacy and Safety of Wenxin Granule Combined With Metoprolol in the Treatment of Arrhythmia of Coronary Heart Disease in the Elderly. Public Med. Forum Mag. (25), 3523–3525. 10.13241/j.cnki.pmb.2018.01.029 [DOI] [Google Scholar]
  28. Guo L. Q. (2018). Observation on the Effect of Wenxin Granule Combined With Amiodarone in the Treatment Of Coronary Heart Disease and Arrhythmia. Mod. Diagn. Treat. (9), 1392–1394. 10.14163/j.cnki.11-5547/r.2017.23.058 [DOI] [Google Scholar]
  29. Guo Y. H., Tai X. (2020). Analysis of the Effect of Wenxin Granule Combined With Metoprolol in the Treatment of Elderly Patients With Coronary Heart Disease and Arrhythmia. China Pract. Med. (18), 118–120. 10.16282/j.cnki.cn11-9336/r.2019.26.026 [DOI] [Google Scholar]
  30. Han X. Q., Wang W. Y. (2014). Clinical Effect of Wenxin Granule Combined With Metoprolol in the Treatment of Arrhythmia Caused by Coronary Heart Disease. J. Mod. Med. Health (24), 3813–3814. 10.13493/j.issn.1672-7878.2016.04-081 [DOI] [Google Scholar]
  31. He L. Z., Xie G. T., Nong S. X., Shi L. F. (2020). Analysis of the Effect of Wenxin Granule Combined With Metoprolol in the Treatment of Patients With Coronary Heart Disease Complicated With Ventricular Arrhythmia. China Med. Pharm. (8), 60–62+120. 10.14164/j.cnki.cn11-5581/r.2019.05.051 [DOI] [Google Scholar]
  32. Hou A. F. (2018). Evaluation of the Effect of Amiodarone Combined With Metoprolol in the Treatment of Coronary Heart Disease With Arrhythmia. Contemp. Med. Forum (7), 125–126. 10.16282/j.cnki.cn11-9336/r.2020.26.012 [DOI] [Google Scholar]
  33. Hou J. H. (2019). The Effect of Wenxin Granule Combined With Metoprolol in the Treatment of Coronary Heart Disease Complicated With Ventricular Arrhythmia. Clin. Med. (8), 114–115. 10.19613/j.cnki.1671-3141.2019.88.100 [DOI] [Google Scholar]
  34. Hou M. Q., Zhang C. Y., Qiu L. (2015). Effect of Shensong Yangxin Capsules Combined with Metoprolol in the Treatment of Elderly Patients with Coronary Heart Disease and Arrhythmia. Chin. J. Difficult Complic. Cases (5), 508–510+515. 10.15912/j.cnki.gocm.2017.06.161 [DOI] [Google Scholar]
  35. Hu H., Yang X. F. (2018). Comparison of Curative Effect of Amiodarone and Propafenone on Patients With Coronary Heart Disease and Arrhythmia. Gansu Sci. Tech. (6), 77–78. 10.19435/j.1672-1721.2020.23.063 [DOI] [Google Scholar]
  36. Hu W. Z. (2016). A Randomized Controlled Evaluation of Wenxin Granules and Metoprolol in the Treatment of Coronary Heart Disease with Ventricular Arrhythmia. China Cont. Med. Edu. (12), 159–160. 10.16282/j.cnki.cn11-9336/r.2019.30.025 [DOI] [Google Scholar]
  37. Huang X. D. (2016). Clinical Observation of Wenxin Granule Combined With Metoprolol in the Treatment Of Coronary Heart Disease With Ventricular Arrhythmia. Cardiovasc. Dis. J. Integr. Tradit. Chin. West. Med. (3), 51–52. 10.16282/j.cnki.cn11-9336/r.2019.25.038 [DOI] [Google Scholar]
  38. Huang Y. P. (2018). The Effect of Amiodarone Combined With Metoprolol in the Treatment of Senile Coronary Heart Disease Complicated With Arrhythmia. Guide China Med. (15), 120–121. 10.14164/j.cnki.cn11-5581/r.2021.06.068 [DOI] [Google Scholar]
  39. Huo J. X. (2019). Analysis of Clinical Efficacy of Wenxin Granule Combined With Metoprolol in the Treatment Of 128 Patients With Coronary Heart Disease and Arrhythmia. Cardiovasc. Dis. J. Integr. Tradit. Chin. West. Med. (30), 40–41. 10.19613/j.cnki.1671-3141.2018.83.121 [DOI] [Google Scholar]
  40. Huo X. Y. (2019). The Effect of Atenolol Combined With Amiodarone in the Treatment of Coronary Heart Disease With Arrhythmia. Cardiovasc. Dis. J. Integr. Tradit. Chin. West. Med. (7), 197. 10.15887/j.cnki.13-1389/r.2020.12.020 [DOI] [Google Scholar]
  41. Jiang X. J., Liu F. P., Tu S. H. (2017). Observation on the Effect of Amiodarone Combined With Wenxin Granule in the Treatment of Senile Coronary Heart Disease With Arrhythmia. China Mod. Med. (28), 141–143. 10.16282/j.cnki.cn11-9336/r.2020.06.035 [DOI] [Google Scholar]
  42. Jin F. P., Gao Z. H., Meng Y. T., He Q. (2018). The Effect of Amiodarone on the Changes of Electrocardiogram in Patients With Coronary Heart Disease And Rapid Ventricular Arrhythmia. Pract. Clin. J. Integr. Tradit. Chin. West. Med. 10, 139–140. 10.16282/j.cnki.cn11-9336/r.2020.09.047 [DOI] [Google Scholar]
  43. Jin P. (2019). Wenxin Granule Combined With Metoprolol in the Treatment of Coronary Heart Disease Arrhythmia. Cardiovasc. Dis. J. Integr. Tradit. Chin. West. Med. (25), 51+66. 10.15887/j.cnki.13-1389/r.2019.12.001 [DOI] [Google Scholar]
  44. Ju Y. H. (2016). Observation of the Curative Effect of Amiodarone in the Treatment of Patients With Coronary Heart Disease and Ventricular Arrhythmia. Med. J. Chin. People’s Health (8), 7–8+11. 10.19528/j.issn.1003-3548.2019.08.045 [DOI] [Google Scholar]
  45. Kai-Qiang P. U., Luo X. J., Yong-Mei H. U. (2019). Application of Information Management in Incidence Monitoring of Coronary Heart Disease. World Latest Medicine Information. Available at: http://eprints.qut.edu.au/25065/ . [Google Scholar]
  46. Katta N., Loethen T., Lavie C. J., Alpert M. A. (2020). Obesity and Coronary Heart Disease: Epidemiology, Pathology, and Coronary Artery Imaging. Curr. Probl. Cardiol., 100655. 10.1016/j.cpcardiol.2020.100655 [DOI] [PubMed] [Google Scholar]
  47. Klotzbaugh R. J., Martin A., Turner J. R. (2020). Drug-Induced Proarrhythmia: Discussion and Considerations for Clinical Practice. JAAPA 33, 1–7. 10.1097/01.JAA.0000651776.53223.e7 [DOI] [PubMed] [Google Scholar]
  48. Lavon O., Goldman R. (2019). Adherence to Monitoring Guidelines of Amiodarone Adverse Reactions. Health Serv. Res. Manag. Epidemiol. 6, 2333392819844635. 10.1177/2333392819844635 [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Li H. (2020). To Evaluate the Clinical Efficacy of Wenxin Granules Combined With Metoprolol on Elderly Patients With Coronary Heart Disease With Arrhythmia. Guide China Med. (8), 169–170. 10.15912/j.cnki.gocm.2020.20.067 [DOI] [Google Scholar]
  50. Li J. (2018). Effect of Shensong Yangxin Capsule and Metoprolol on Coronary Heart Disease Complicated with Ventricular Arrhythmia. Chin. J. Heart Heart Rhythm (4), 215–218. 10.14163/j.cnki.11-5547/r.2016.07.116 [DOI] [Google Scholar]
  51. Li L. (2020). Clinical Effect and Safety Analysis of Shensongyangxin Capsule Combined With Metoprolol Succinate Sustained-Release Tablets in the Treatment of Arrhythmia of Coronary Heart Disease in the Elderly. J. Clin. Rational Drug Use (23), 1–2+21. 10.16282/j.cnki.cn11-9336/r.2019.15.019 [DOI] [Google Scholar]
  52. Li M., Li H., Chen H. W., Zhu Y. F., Huang J. Y., Xue W., et al. (2018). Amiodarone in the Treatment of Coronary Heart Disease Arrhythmia and its Effect on Hemodynamics. Prog. Mod. Biomed. (1), 130–134. 10.15912/j.cnki.gocm.2018.29.139 [DOI] [Google Scholar]
  53. Li M. M. (2020). The Effect of Amiodarone Combined With Atenolol in the Treatment of Patients With Coronary Heart Disease Complicated By Arrhythmia. Med. J. Chin. People’s Health (16), 22–23+26. 10.16282/j.cnki.cn11-9336/r.2019.07.145 [DOI] [Google Scholar]
  54. Li P. Z., Zhang Y., Tan F. (2020). Effectiveness and Safety of Amiodarone in Adjuvant Treatment of Coronary Heart Disease With Tachyarrhythmia. Cardiovasc. Dis. J. Integr. Tradit. Chin. West. Med. (9), 61–62. 10.16282/j.cnki.cn11-9336/r.2019.15.019 [DOI] [Google Scholar]
  55. Li S. M. (2020). The Clinical Efficacy and Safety Evaluation Analysis of Wenxin Granule Combined With Metoprolol in the Treatment Of Coronary Heart Disease With Arrhythmia. Cardiovasc. Dis. J. Integr. Tradit. Chin. West. Med. (4), 32. 10.14163/j.cnki.11-5547/r.2016.02.106 [DOI] [Google Scholar]
  56. Li X. T., Dong H., Sang S. D. (2020). Clinical Study on Treatment of 80 Cases of Senile Coronary Heart Disease Arrhythmia with Shensongyangxin Capsules and Metoprolol Succinate Sustained Release Tablets. Guizhou Med. J. (5), 782–784. 10.15887/j.cnki.13-1389/r.2018.07.006 [DOI] [Google Scholar]
  57. Li Y. C. (2018). Clinical Experience of Amiodarone Combined With Metoprolol in the Treatment of Coronary Heart Disease and Arrhythmia. J. China Prescrip. Drug (9), 58–59. 10.19738/j.cnki.psy.2020.06.146 [DOI] [Google Scholar]
  58. Li Z. Q. (2014). To Observe the Efficacy of Metoprolol Combined With Wenxin Granule in the Treatment of Arrhythmia of Coronary Heart Disease in the Elderly. Cardiovasc. Dis. J. Integr. Tradit. Chin. West. Med. (13), 37–38. 10.16282/j.cnki.cn11-9336/r.2020.04.026 [DOI] [Google Scholar]
  59. Liang W. T. (2018). The Effect of Wenxin Granule Combined With Amiodarone in the Treatment of Elderly Coronary Heart Disease With Arrhythmia. Clin. Med. Eng. (3), 341–342. 10.15887/j.cnki.13-1389/r.2020.23.001 [DOI] [Google Scholar]
  60. Lie H. L. (2018). The Effect of Wenxin Granule Combined With Metoprolol in the Treatment of Senile Coronary Heart Disease With Arrhythmia. Contemp. Med. Forum (6), 137–138. 10.16282/j.cnki.cn11-9336/r.2020.30.053 [DOI] [Google Scholar]
  61. Liu H. Y. (2017). Efficacy of Potassium Magnesium Aspartate Combined With Amiodarone in the Treatment of Coronary Heart Disease With Ventricular Arrhythmia and its Influence on the Pr Interval and Qrs Time Limit of Electrocardiogram. Cardiovasc. Dis. J. integrated traditional Chin. West. Med. (21), 41+44. 10.15912/j.cnki.gocm.2018.31.089 [DOI] [Google Scholar]
  62. Liu J. Y. (2018). Clinical Effect Observation of Amiodarone in the Treatment of Coronary Heart Disease Tachyarrhythmia. Med. J. Chin. People’s Health (24), 50–51. 10.15887/j.cnki.13-1389/r.2019.36.020 [DOI] [Google Scholar]
  63. Liu Y. T., Wang Y. F. (2015). Analysis of the Effect of Metoprolol Tartrate Tablets Combined With Wenxin Granules in the Treatment of Ventricular Arrhythmia in Elderly Patients With Coronary Heart Disease. Contemp. Med. Forum (8), 149–150. 10.15912/j.cnki.gocm.2017.06.161 [DOI] [Google Scholar]
  64. Liu Z. Q. (2018). Application Effect of Wenxin Granule Combined With Amiodarone in the Clinical Treatment Of Coronary Heart Disease and Arrhythmia. World Latest Med. Inf. (83), 150+152. 10.19381/j.issn.1001-7585.2012.12.003 [DOI] [Google Scholar]
  65. Long Y. X. (2019). Analysis of the Effect of Atenolol and Amiodarone in the Treatment of Coronary Heart Disease With Arrhythmia. Cardiovasc. Dis. J. Integr. Tradit. Chin. West. Med. 18, 45. 10.16282/j.cnki.cn11-9336/r.2017.21.026 [DOI] [Google Scholar]
  66. Luo Y. L. (2016). Effect of Shensong Yangxin Capsules Combined with Metoprolol Sustained Release Tablets on Arrhythmia of Coronary Heart Disease in the Elderly. Clin. Med. (9), 117–119. 10.16662/j.cnki.1674-0742.2015.18.029 [DOI] [Google Scholar]
  67. Lv W. X., Fang Y. L., Zhao X. (2020). Analysis of Curative Effect of Wenxin Granule Combined With Metoprolol in the Treatment Of Coronary Heart Disease With Arrhythmia. Cardiovasc. Dis. J. Integr. Tradit. Chin. West. Med. (14), 45. 10.13638/j.issn.1671-4040.2019.02.029 [DOI] [Google Scholar]
  68. Meng Z. L. (2018). Clinical Effect of Atenolol Combined With Amiodarone in The Treatment of Coronary Heart Disease With Arrhythmia. Henan Med. Res. (21), 3982–3983. 10.15887/j.cnki.13-1389/r.2019.36.020 [DOI] [Google Scholar]
  69. Pan X. L., Li W. J., Deng T. (2017). Clinical Observation of Amiodarone and Metoprolol in the Treatment of Elderly Patients with Coronary Heart Disease Complicated with Arrhythmia. Contemp. Med. (29), 9–11. 10.16281/j.cnki.jocml.2020.07.134 [DOI] [Google Scholar]
  70. Peng M. Y. (2017). Clinical Value Observation of Metoprolol Combined With Wenxin Granule in the Treatment Of Coronary Heart Disease Arrhythmia. Chin. Commun. Physician (17), 90–91. 10.13586/j.cnki.yjyx1984.2020.01.063 [DOI] [Google Scholar]
  71. Peng X. P., Liu J. (2019). Clinical Study on Shensong Yangxin Capsule Combined with Metoprolol in Treating Coronary Heart Disease with Arrhythmia. Henan Med. Res. (10), 1862–1864. 10.13638/j.issn.1671-4040.2018.10.031 [DOI] [Google Scholar]
  72. Qian Y. P. (2015). To Explore The Effect of Wenxin Granule Combined With Metoprolol in the Treatment of Arrhythmia of Coronary Heart Disease in the Elderly. World Latest Med. Inf. 71, 86. 10.14163/j.cnki.11-5547/r.2015.20.108 [DOI] [Google Scholar]
  73. Qu Y. H. (2016). Observation on the Clinical Effect of Amiodarone Combined With Metoprolol in the Treatment of Elderly Coronary Heart Disease With Arrhythmia. China Pract. Med. (2), 146–147. 10.15912/j.cnki.gocm.2019.19.107 [DOI] [Google Scholar]
  74. Ren Z. P. (2018). The Effect of Amiodarone Combined With Metoprolol on Electrocardiogram in Elderly Patients With Coronary Heart Disease and Arrhythmia. Pharm. Today (3), 187–189. 10.13593/j.cnki.51-1501/r.2016.02.086 [DOI] [Google Scholar]
  75. Ren Z. R. (2020). The Effect of Wenxin Granule Combined With Amiodarone in the Treatment of Coronary Heart Disease and Arrhythmia on Hemorheological Indexes. Cardiovasc. Dis. J. Integr. Tradit. Chin. West. Med. (3), 70–71. 10.19613/j.cnki.1671-3141.2018.40.101 [DOI] [Google Scholar]
  76. Ruan W. S. (2020). The Effect of Wenxin Granule Combined With Metoprolol in Patients With Coronary Heart Disease and Arrhythmia. Pract. Clin. J. Integr. Tradit. Chin. West. Med. (3), 61–62. 10.16458/j.cnki.1007-0893.2019.12.049 [DOI] [Google Scholar]
  77. Shi L. (2020). The Application Value of Amiodarone in the Treatment of Coronary Heart Disease, Chronic Heart Failure and Ventricular Arrhythmia. Clin. Res. Pract. (27), 36–37. 10.19347/j.cnki.2096-1413.202027015 [DOI] [Google Scholar]
  78. Shi S., Shi J., Jia Q., Shi S., Yuan G., Hu Y. (2020). Efficacy and safety of ShenSongYangXin Capsule Combined With Antiarrhythmic Drugs For Atrial Fibrillation: A Protocol For Systematic Review And Network Meta-Analysis. Medicine 99 (38), e22367. 10.1097/MD.0000000000022367 [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Shi-Jun J. I . (2019). Effect of Combination of Wenxin Granule and Metoprolol Tartrate on Arrhythmia in Patients with Coronary Heart Disease. Heilongjiang Med. J. 10.14163/j.cnki.11-5547/r.2019.20.045 [DOI] [Google Scholar]
  80. Song M. Y., Liu Y., Deng D. Z. (2019). Clinical Efficacy and Safety of Shensongyangxin Capsule Combined With Metoprolol Tartrate in the Treatment of Coronary Heart Disease With Arrhythmia. Med. Recapitulate (1), 184–188. 10.16252/j.cnki.issn1004-0501-2013.08.043 [DOI] [Google Scholar]
  81. Sun J. F., Gu X. W. (2019). Clinical Efficacy and Safety of Amiodarone in the Treatment Of Coronary Heart Disease With Chronic Heart Failure and Ventricular Arrhythmia. Knowledge Cardiovasc. Dis. Prev. Treat. (36), 42–43. 10.16282/j.cnki.cn11-9336/r.2019.26.026 [DOI] [Google Scholar]
  82. Sun L. L. (2018). Effect of Shensongyangxin Capsules and Metoprolol Sustained-Release Tablets on Arrhythmia of Coronary Heart Disease in the Elderly. Guide China Med. (29), 176. 10.15912/j.cnki.gocm.2018.32.091 [DOI] [Google Scholar]
  83. Sun S. (2020). Comparison of the Efficacy of Amiodarone Monotherapy and Wenxin Granule Combined With Amiodarone in the Treatment of Coronary Heart Disease Arrhythmia. Int. Infect. Dis. (2), 121. 10.16282/j.cnki.cn11-9336/r.2020.36.136 [DOI] [Google Scholar]
  84. Tan S. L., Gan Z. P., Li Z. L. (2020). Effect of Amiodarone on LVEF, LVESV and LVEDV in Patients with Coronary Heart Disease, Chronic Heart Failure and Ventricular Arrhythmia. Electron. J. Mod. Med. Health Res. (5), 23–24. 10.14163/j.cnki.11-5547/r.2020.30.056 [DOI] [Google Scholar]
  85. Wang C., Wang Z., Xie S. Y., Liu B., Yan X. H., Wang J. J. (2018). Effect of Amiodarone and Wenxin Granules on Arrhythmia of Coronary Heart Disease. J. North Pharmacy Modern Diagn. Treat. (5), 102–103. 10.15912/j.cnki.gocm.2017.20.131 [DOI] [Google Scholar]
  86. Wang G. C. (2018). Clinical Analysis of Amiodarone in the Treatment of Coronary Heart Disease With Ventricular Arrhythmia. Electron. J. Gen. Stomatology (18), 130–131. 10.19613/j.cnki.1671-3141.2019.41.007 [DOI] [Google Scholar]
  87. Wang G. N., Li Y., Zhang J., Zhang Y. B. (2018). Clinical Observation of Metoprolol Combined With Amiodarone in the Treatment of Coronary Heart Disease With Arrhythmia. Chin. J. Geriatr. Heart Brain Vessel Dis. (9), 932–935. 10.19435/j.1672-1721.2017.32.116 [DOI] [Google Scholar]
  88. Wang H. (2013). Clinical Observation of Amiodarone in the Treatment of 67 Cases of Coronary Heart Disease with Ventricular Arrhythmia. Guide China Med. (33), 366–367. 10.15912/j.cnki.gocm.2018.12.015 [DOI] [Google Scholar]
  89. Wang K. (2018). Effect Analysis of Wenxin Granule Combined With Amiodarone in Coronary Heart Disease Arrhythmia. Tibet Med. (5), 41–42. 10.14035/j.cnki.hljyy.2016.02.044 [DOI] [Google Scholar]
  90. Wang L. (2016). Efficacy and Safety Evaluation of Wenxin Granule Combined With Metoprolol on Arrhythmia in Patients With Coronary Heart Disease. Anti-Infection Pharm. (4), 925–927. 10.13586/j.cnki.yjyx1984.2020.01.063 [DOI] [Google Scholar]
  91. Wang L., Gao Y., Yuan Q. C. (2020). Clinical Efficacy of Amiodarone in the Treatment Of Coronary Heart Disease Tachyarrhythmia and its Influence On Patient’s Hemodynamics. Jilin Med. J. (4), 792–794. 10.15912/j.cnki.gocm.2019.14.063 [DOI] [Google Scholar]
  92. Wang X. J. (2020). Clinical Study of Shensong Yangxin Capsule Combined With Metoprolol Tartrate in the Treatment Of 70 Patients With Coronary Heart Disease and Arrhythmia. Capital Med. (5), 78. 10.15912/j.cnki.gocm.2020.17.071 [DOI] [Google Scholar]
  93. Wang Y., Qi L. P. (2016). Clinical Observation of Shensong Yangxin Capsule Combined with Metoprolol in Treating Arrhythmia of Coronary Heart Disease with Qi Deficiency and Stasis Obstruction. J. Chengdu Univ. Traditional Chin. Med. (2), 86–89. 10.14164/j.cnki.cn11-5581/r.2017.24.058 [DOI] [Google Scholar]
  94. Wang Z. Y. (2017). Effect Analysis of Wenxin Granule and Metoprolol in the Treatment of Arrhythmia of Coronary Heart Disease in the Elderly. China Rural Health 10, 72. 10.19335/j.cnki.2096-1219.2019.29.073 [DOI] [Google Scholar]
  95. Wu G. (2016). Clinical Study on Amiodarone in Treating Tachyarrhythmia of Coronary Heart Disease in Emergency. Trauma Crit. Care Med. 03, 141–143. 10.13638/j.issn.1671-4040.2020.03.031 [DOI] [Google Scholar]
  96. Xiao Y. Q., Chen S. Z., Zhuang Z. K. (2017). Study on the Effectiveness of Wenxin Granule Combined With Β-Receptor Blocker in the Treatment of Coronary Heart Disease and Arrhythmia. Chin. J. Mod. Drug Appl. (24), 104–105. 10.15912/j.cnki.gocm.2018.29.139 [DOI] [Google Scholar]
  97. Xu P. (2019). To Analyze the Clinical Efficacy of Metoprolol Tartrate Combined With Amiodarone in the Treatment of Coronary Heart Disease With Arrhythmia. J. Clin. Med. Lit. (45), 170–171. 10.15887/j.cnki.13-1389/r.2020.12.020 [DOI] [Google Scholar]
  98. Xu X. Y. (2019). Evaluation of the Efficacy of Shensongyangxin Capsule Combined With Metoprolol in the Treatment of Coronary Heart Disease Arrhythmia. Shanghai Med. Pharm. J. (4), 21–23. 10.13638/j.issn.1671-4040.2018.10.071 [DOI] [Google Scholar]
  99. Xu Y. (2018). Therapeutic Effect of Amiodarone Combined With Metoprolol in the Treatment of Coronary Heart Disease Arrhythmia. J. Cardiovasc. Surg. (3), 403–404. 10.15887/j.cnki.13-1389/r.2019.36.020 [DOI] [Google Scholar]
  100. Xun S. L. (2017). Effect of Wenxin Granules Combined with Metoprolol Tablets on Arrhythmia Caused by Coronary Heart Disease. Contemp. Med. Forum (9), 113–114. 10.19347/j.cnki.2096-1413.201706011 [DOI] [Google Scholar]
  101. Xun Z. F. (2020). To Observe the Efficacy and Safety of Amiodarone in the Treatment of Coronary Heart Disease With Ventricular Arrhythmia. Knowledge Cardiovasc. Dis. Prev. Treat. (15), 32–34. 10.16282/j.cnki.cn11-9336/r.2019.15.019 [DOI] [Google Scholar]
  102. Yan-Hua X. U . (2018). Evaluation on Nursing Intervention Way and Application Effect of Coronary Heart Disease Arrhythmia. China Forgn Med. Treat. [Google Scholar]
  103. Yang C., Zhang L. L. (2019). Observation of the Clinical Efficacy of Potassium Magnesium Aspartate and Amiodarone in the Treatment of Coronary Heart Disease With Ventricular Arrhythmia. Xinjiang Med. J. (2), 180–182. 10.13241/j.cnki.pmb.2018.01.029 [DOI] [Google Scholar]
  104. Yang F. C., Sun Z. G., Feng Z. H. (2017). Clinical Evaluation of Amiodarone on Patients With Coronary Heart Disease, Chronic Heart Failure and Ventricular Arrhythmia. Anti-Infection Pharm. (2), 358–360. 10.14035/j.cnki.hljyy.2016.06.043 [DOI] [Google Scholar]
  105. Yang X. H. (2017). Effect of Wenxin Granules Combined with Amiodarone on Ventricular Arrhythmia of Coronary Heart Disease. .Guide China Med. (20), 161–162. 10.16282/j.cnki.cn11-9336/r.2020.13.056 [DOI] [Google Scholar]
  106. Yang Y. (2018). The Effect of Amiodarone Combined With Metoprolol on the Changes of Electrocardiogram and the Improvement of Heart Rate in Elderly Patients With Coronary Heart Disease Complicated With Arrhythmia. J. Med. Forum 10, 116–119. 10.13493/j.issn.1672-7878.2017.02-044 [DOI] [Google Scholar]
  107. Yang Y. X., Xi Y. J. (2020). Efficacy and Safety Evaluation of Atenolol Combined With Amiodarone in the Treatment of Coronary Heart Disease With Arrhythmia. Knowledge Cardiovasc. Dis. Prev. Treat. (1), 23–25. 10.15912/j.cnki.gocm.2020.20.067 [DOI] [Google Scholar]
  108. Ye Y., Chen X., Han J., Jiang W., Natarajan P., Zhao H. (2021). Interactions Between Enhanced Polygenic Risk Scores and Lifestyle for Cardiovascular Disease, Diabetes, and Lipid Levels. Circ. Genomic Precision Med. 14. 10.1161/CIRCGEN.120.003128 [DOI] [PMC free article] [PubMed] [Google Scholar]
  109. Ye Y. F. (2012). Clinical Observation of Amiodarone in the Treatment of 43 Cases of Coronary Heart Disease With Ventricular Arrhythmia. J. Med. Theor. Pract. (12), 1410–1411. 10.16281/j.cnki.jocml.2017.73.083 [DOI] [Google Scholar]
  110. Yi Q. (2018). Clinical Observation of Amiodarone Combined with Metoprolol Tartrate in the Treatment of Coronary Heart Disease Complicated with Tachyarrhythmia. J. Clin. Rational Drug Use (7), 12–13. 10.14163/j.cnki.11-5547/r.2017.23.058 [DOI] [Google Scholar]
  111. Yi W. L. (2019). Clinical Study of Amiodarone Combined With Metoprolol in the Treatment Of Coronary Heart Disease Complicated With Tachyarrhythmia. J. Heze Med. Coll. (4), 45–47. 10.16282/j.cnki.cn11-9336/r.2019.26.026 [DOI] [Google Scholar]
  112. Yong W. U. (2013). Analysis of 188 Cases of Adverse Drug Reaction Induced by Potassium Aspartate and Magnesium Aspartate. Chin. J. Drug Eval. [Google Scholar]
  113. You Y. X. (2017). Clinical Effect of Amiodarone in the Treatment of Emergency Coronary Heart Disease Patients With Tachyarrhythmia. Guangzhou Med. (6), 82–83+96. 10.15912/j.cnki.gocm.2018.11.122 [DOI] [Google Scholar]
  114. Yu F. B. (2018). The Effect of Amiodarone Combined With Metoprolol on the Improvement of Cardiac Function and the Ability of Daily Living in Elderly Patients With Coronary Heart Disease Complicated With Arrhythmia. Clin. Res. (2), 82–83. 10.19435/j.1672-1721.2016.27.010 [DOI] [Google Scholar]
  115. Yu W. (2020). Analysis of the Effect of Combined Use of Metoprolol and Amiodarone in the Treatment of Ventricular Arrhythmia in Coronary Heart Disease. Chin. Med. J. Metallurg. Industry (1), 66. 10.15912/j.cnki.gocm.2018.15.089 [DOI] [Google Scholar]
  116. Yu Z. W., Wei W. F., Liu Y. G. (2015). Clinical Observation of Wenxin Granule Combined With Metoprolol Tartrate in the Treatment of Patients With Coronary Heart Disease and Ventricular Arrhythmia. China J. Pharm. Econ. (11), 26–27. 10.14163/j.cnki.11-5547/r.2020.18.054 [DOI] [Google Scholar]
  117. Yuan J. L. (2017). Clinical Analysis of The Effect of Amiodarone in the Treatment of Coronary Heart Disease Tachyarrhythmia. World Compound Med. (2), 72–74. 10.14164/j.cnki.cn11-5581/r.2017.24.058 [DOI] [Google Scholar]
  118. Yue X. Y. (2018). Clinical Observation of Wenxin Granules Combined with Amiodarone in Treating Arrhythmia of Coronary Heart Disease. Pract. Clin. J. Integrated Traditional Chin. West. Med. 10, 65–66. 10.15887/j.cnki.13-1389/r.2019.36.020 [DOI] [Google Scholar]
  119. Zagkli F., Chronopoulos P., Chiladakis J. (2021). Unexpected Inhibition of Bradycardia Pacing Due to Oversensing in ICD Lead Fracture Associated With Spurious Tachyarrhythmia Detection and Discharges. Indian Pacing Electrophysiol. J. 21, 182–185. 10.1016/j.ipej.2021.02.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  120. Zhang J. W. U. (2016a). Analysis of the Therapeutic Effect of Wenxin Granule and Metoprolol in The Treatment of Arrhythmia of Coronary Heart Disease in The Elderly. China Cont. Med. Edu. (28), 198–199. 10.15912/j.cnki.gocm.2016.31.163 [DOI] [Google Scholar]
  121. Zeng P. (2016). Clinical Effect Analysis of Amiodarone in the Treatment of Emergency Coronary Heart Disease Tachyarrhythmia. World Latest Med. Inf. (49), 146–147. 10.16282/j.cnki.cn11-9336/r.2014.13.084 [DOI] [Google Scholar]
  122. Zhang C. H. (2020). Clinical Analysis of Amiodarone Combined With Atenolol in the Treatment of Coronary Heart Disease With Arrhythmia. Chin. J. Mod. Drug Appl. (3), 132–134. 10.19347/j.cnki.2096-1413.201720007 [DOI] [Google Scholar]
  123. Zhang G. M. (2017). The Effect of Potassium Magnesium Aspartate Combined With Amiodarone in the Treatment of Coronary Heart Disease With Ventricular Arrhythmia And its Influence on The Pr Interval and Qrs Time Limit Of Electrocardiogram. Henan Med. Res. (11), 2031–2032. 10.16282/j.cnki.cn11-9336/r.2014.13.084 [DOI] [Google Scholar]
  124. Zhang H. (2018). Clinical Analysis of Amiodarone Combined With Metoprolol in the Treatment Of Senile Coronary Heart Disease With Arrhythmia. Guide China Med. (31), 118–119. 10.19613/j.cnki.1671-3141.2018.97.078 [DOI] [Google Scholar]
  125. Zhang H. G. (2018). Effect of Amiodarone on Ventricular Arrhythmia in Patients with Coronary Heart Disease and Chronic Heart Failure. Res. Trace Elem. Health (5), 14–15. 10.14163/j.cnki.11-5547/r.2017.23.058 [DOI] [Google Scholar]
  126. Zhang H. M., Sun Y. X., Cai Z. L. (2016). Clinical Observation of Wenxin Granule Combined With Metoprolol in the Treatment of Arrhythmia of Coronary Heart Disease in the Elderly. Mod. Diagn. Treat. 20, 3839–3840. 10.16281/j.cnki.jocml.2015.26.127 [DOI] [Google Scholar]
  127. Zhang J., Zhang D. Y. (2013). Clinical Analysis of Amiodarone in the Treatment of Coronary Heart Disease With Ventricular Arrhythmia. Sichuan Med. J. (8), 1191–1192. 10.14163/j.cnki.11-5547/r.2020.18.054 [DOI] [Google Scholar]
  128. Zhang J. L. (2016b). Clinical Observation on 104 Cases of Coronary Heart Disease Arrhythmia Treated by Wenxin Granules Combined with Amiodarone. World Latest Med. Inf. (12), 106+108. 10.15912/j.cnki.gocm.2019.19.107 [DOI] [Google Scholar]
  129. Zhang J. Q. (2019). Analysis of the Therapeutic Effect of Wenxin Granule and Metoprolol in the Treatment of Arrhythmia of Coronary Heart Disease in the Elderly. Cardiovasc. Dis. J. Integr. Tradit. Chin. West. Med. (3), 147–148. 10.19613/j.cnki.1671-3141.2017.67.072 [DOI] [Google Scholar]
  130. Zhang L. (2017). Clinical Effect Of Wenxin Granule Combined With Metoprolol in the Treatment Of Coronary Heart Disease Complicated With Ventricular Arrhythmia. J. Clin. Med. Lit. (73), 14398–14399. 10.16281/j.cnki.jocml.20180913.001 [DOI] [Google Scholar]
  131. Zhang S. K. (2019). The Effect of Wenxin Granule Combined With Metoprolol in the Treatment of Coronary Heart Disease and Arrhythmia in the Elderly. Chin. J. Rational Drug Use (12), 141–142+145. 10.19613/j.cnki.1671-3141.2018.83.121 [DOI] [Google Scholar]
  132. Zhang T. (2019). Effect of Amiodarone on Coronary Heart Disease with Tachyarrhythmia. Med. J. Chin. People’s Health (2), 21–23. 10.15912/j.cnki.gocm.2013.33.214 [DOI] [Google Scholar]
  133. Zhang X. (2019). Clinical Effect of Amiodarone Combined With Metoprolol in the Treatment Of Patients With Coronary Heart Disease Complicated With Tachyarrhythmia. Med. equipment (20), 109–110. 10.15887/j.cnki.13-1389/r.2019.12.001 [DOI] [Google Scholar]
  134. Zhang X. D. (2015). Clinical Observation of Wenxin Granules Combined with Metoprolol in Treating Ventricular Arrhythmia in Elderly Patients with Coronary Heart Disease. China’s Naturopathy 10, 56–57. 10.14163/j.cnki.11-5547/r.2020.18.054 [DOI] [Google Scholar]
  135. Zhang X. S. (2020). Clinical Analysis of Amiodarone Combined With Metoprolol in the Treatment Of Senile Coronary Heart Disease With Arrhythmia. Guide China Med. (17), 151–152. 10.14164/j.cnki.cn11-5581/r.2020.03.063 [DOI] [Google Scholar]
  136. Zhang Y., Xu J., Cardiology D. O. (2019). Application of RFCA in Patients With Ventricular Arrhythmia Originating From Mitral Valve According to the Characteristics of Surface ECG. Chin. J. Geriatr. Heart Brain Vessel Dis. [Google Scholar]
  137. Zhang Y. Q., Chen Y., Liu Z. L., Lin G. J. (2016). The Therapeutic Effect and Safety of Metoprolol Combined With Wenxin Granule in Elderly Patients With Coronary Heart Disease and Arrhythmia. Heilongjiang Med. J. (6), 1130–1132. 10.15912/j.cnki.gocm.2020.08.129 [DOI] [Google Scholar]
  138. Zhao J. G., Long J. X. (2017). Observation on the Effect of Amiodarone Combined With Metoprolol in the Treatment of Coronary Heart Disease Complicated With Arrhythmia in the Elderly. Clin. Med. Res. Pract. (20), 15–16. 10.16282/j.cnki.cn11-9336/r.2020.13.056 [DOI] [Google Scholar]
  139. Zhao J. H., Wu W., Wang X. P. (2020). Effect of Amiodarone Combined with Metoprolol on Arrhythmia of Coronary Heart Disease. China Mod. Med. (25), 50–52+60. 10.16281/j.cnki.jocml.2020.14.134 [DOI] [Google Scholar]
  140. Zhao Y. L. (2018). Analysis of Curative Effect of Wenxin Granule Combined With Metoprolol in Treatment of Arrhythmia of Coronary Heart Disease. Guide China Med. (12), 22+24. 10.14163/j.cnki.11-5547/r.2017.23.058 [DOI] [Google Scholar]
  141. Zhen X. M. (2019). Observation of the Clinical Effect of Amiodarone Combined With Metoprolol on Coronary Heart Disease Complicated With Arrhythmia. Pract. Clin. J. Integr. Tradit. Chin. West. Med. (2), 61–62. 10.16281/j.cnki.jocml.2017.03.021 [DOI] [Google Scholar]
  142. Zhou H. Y. (2016). Clinical Efficacy of Wenxin Granule Combined With Metoprolol in the Treatment of Arrhythmia of Coronary Heart Disease in the Elderly. Contemp. Med. (27), 152–153. 10.16282/j.cnki.cn11-9336/r.2019.03.112 [DOI] [Google Scholar]
  143. Zhou Q. (2016). Effect of Shensong Yangxin Capsules and Metoprolol Sustained Release Tablets on Patients with Ventricular Arrhythmia and Coronary Heart Disease. Med. J. Chin. People’s Health (7), 80+99. 10.16282/j.cnki.cn11-9336/r.2020.14.036 [DOI] [Google Scholar]
  144. Zhou T. (2019). Effect of Amiodarone Combined with Wenxin Granules in Treating Senile Coronary Heart Disease with Arrhythmia. Cardiovasc. Dis. J. Integrated Traditional Chin. West. Med. (26), 36. 10.19613/j.cnki.1671-3141.2018.83.121 [DOI] [Google Scholar]
  145. Zhou Y. (2015). The Effect of Wenxin Granule Combined With Metoprolol in the Treatment of Arrhythmia of Coronary Heart Disease in the Elderly. Knowledge Cardiovasc. Dis. Prev. Treat. (12), 68–69. 10.19435/j.1672-1721.2018.25.017 [DOI] [Google Scholar]
  146. Zhou Y. F. (2015). Clinical Observation of Metoprolol Combined With Wenxin Granule in the Treatment of Coronary Heart Disease Arrhythmia. Chin. Foreign Med. Res. 05, 10–12. 10.14163/j.cnki.11-5547/r.2020.18.054 [DOI] [Google Scholar]
  147. Zhu K. (2019). Analysis of the Clinical Effect of Metoprolol Combined With Wenxin Granule in the Treatment of Elderly Patients With Coronary Heart Disease and Arrhythmia. Smart Healthc. (29), 165–166. 10.16281/j.cnki.jocml.2019.10.130 [DOI] [Google Scholar]
  148. Zhu X. P. (2018). Study on the Curative Effect of Metoprolol Combined With Wenxin Granule in the Treatment of Coronary Heart Disease With Arrhythmia. J. Clin. Med. Lit. (19), 172–173. 10.14163/j.cnki.11-5547/r.2019.13.046 [DOI] [Google Scholar]
  149. Zhuang X. N. (2017). Therapeutic Effect of Wenxin Granule Combined With Amiodarone On Arrhythmia Of Coronary Heart Disease. World Latest Med. Inf. (22), 69+71. 10.16282/j.cnki.cn11-9336/r.2018.19.001 [DOI] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Click here for additional data file. (13.5KB, docx)
Click here for additional data file. (155.7KB, docx)
Click here for additional data file. (20.4KB, xlsx)

Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES